Volume 13 Supplement 4

Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection

Meeting abstracts

Glasgow, UK7-11 November 2010

Page 1 of 6

Why suppression of HIV replication does not always make everything better

Authors: M Lederman

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):K1

Content type: Keynote presentation Published on: 8 November 2010
- View Full Text
- View PDF
The public health implications of antiretroviral therapy – 2011 and beyond

Authors: KM De Cock

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):K2

Content type: Keynote presentation Published on: 8 November 2010
- View Full Text
- View PDF
ART achievements and challenges in Africa

Authors: J Hakim

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):K3

Content type: Keynote presentation Published on: 8 November 2010
- View Full Text
- View PDF
O111. The changing face of HIV resistance; HIV drug resistance north and south — what's next?

Authors: J Schapiro

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O1

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O112. International perspectives on adherence and resistance to HIV antiretroviral therapy

Authors: D Bangsberg

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O2

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O113. Adherence to antiretroviral treatment regimens and correlation with risk of hospitalization among commercially insured HIV patients in the US

Authors: PE Sax, JL Meyers, MJ Mugavero and KL Davis

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O3

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O114. Long-term probability of detecting drug-resistant HIV in patients starting antiretroviral therapy within the first year of HIV infection

Authors: S Lodi, C Kücherer, AM Bakken Kran, B Masquelier, A d'Arminio Monforte, J Gill, D Dunn, D Pillay and K Porter

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O4

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O115. Low-level residual viremia and risk of virological failure

Authors: G Cologni, L Soavi, S Leone, D Valenti, A Callegaro, G Gregis, F Suter and F Maggiolo

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O5

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O116. The EuResist expert model for customised HAART optimisation: 2010 update and extension to newest compounds

Authors: A Pironti, A Sönnerborg, M Zazzi, R Kaiser, D Struck, B Clotet, ÀM Vandamme, F Incardona, T Lengauer, M Rosen-Zvi and M Prosperi

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O6

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O121. Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing

Authors: LPR Vandekerckhove, AMJ Wensing, R Kaiser, F Brun-Vezinet, B Clotet, A De Luca, S Dressler, F Garcia, AM Geretti, T Klimkait, K Korn, B Masquelier, CF Perno, J Schapiro, V Soriano, A Sönnerborg…

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O7

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O122. Calibration and accuracy of the geno2pheno co-receptor algorithm for predicting HIV tropism for single and triplicate measurements of V3 genotype

Authors: LC Swenson, D Knapp and PR Harrigan

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O8

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O123. Short-term variation of HIV tropism readouts in the absence of CCR5 antagonists

Authors: CJ Brumme, W Dong, D Chan, T Mo, LC Swenson, C Woods, J Demarest, J Heera, H Valdez and PR Harrigan

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O9

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O124. Impact of baseline HIV-1 tropism on viral response and CD4 gains in antiretroviral-naïve patients

Authors: E Seclén, M Gonzalez, L Martín-Carbonero, H Gellermann, V Cairns, M Distel, W Kadus, V Soriano and E Poveda

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O10

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O125. Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients

Authors: H Valdez, D Chapman, P Biswai, M Lewis, C Craig, J Heera, S Ellery, LC Swenson and PR Harrigan

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O11

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O131. Treatment as prevention within the framework of current guidelines

Authors: J Montaner

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O12

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O132. Treatment-as-prevention: stopping the epidemic of HIV

Authors: B Williams

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O13

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O133. Test and treat — community perspectives

Authors: B Spire

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O14

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O134. HIV treatment as prevention — human rights issues

Authors: J Amon

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O15

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O135. A pilot study to determine the prevalence of HIV in persons presenting for care with selected conditions: preliminary results from the HIV in Europe study

Authors: A Sönnerborg, A Mocroft, JD Lundgren, D Raben, J Gatell, A Vassilenko, V Hadziosmanovic, J Bergovac, H Sørensen, M Cusini, N Clumeck, B Gazzard, J Rockstroh, M Zuin and A D'Arminio Monforte

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O16

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O211. The state of PI monotherapy and NRTI-sparing therapy

Authors: JR Arribas

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O17

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O212. Ritonavir-boosted protease inhibitor monotherapy is 6% less effective than combination antiretroviral therapy in a meta-analysis

Authors: WFW Bierman, EH Humphreys, MA van Agtmael, CA Boucher and GW Rutherford

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O18

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O213. Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial

Authors: N Clumeck, JR Arribas, P Pulick, G Fätkenheuer, A Hill, Y Van Delft and C Moecklinghoff

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O19

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
O214. Virological findings from the SARA trial: boosted PI monotherapy as maintenance second-line ART in Africa

Authors: D Pillay, R Goodall, CF Gilks, D Yirrell, D Gibb, M Spyer, P Kaleebu, P Munderi, C Kityo, A McCormick, J Nkalubo, F Lyagoba, M Chirara and J Hakim

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O20

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
0215. Virological outcomes in ARV-naïve patients switching or not from a first successful boosted PI-regimen to efavirenz, nevirapine or abacavir regimens

Authors: T Bommenel, JL Meynard, O Launay, A Simon, A Mahamat, V Martinez, J Gilquin, C Katlama, AS Lascaux, C Pradier, E Rouveix, D Costagliola and S Abgrall

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O21

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
0221. The clinical development of NRTIs — cautionary tales

Authors: D Cooper

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O22

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
0222. Major issues and their solutions in the management of HIV and TB — from the laboratory to the patient and population

Authors: M Schechter

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O23

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
0223. Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children

Authors: C Zhang, P Denti, USH Simonsson, G Maartens, MO Karlsson and H McIlleron

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O24

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
0231. Growing old with HIV — dealing with co-morbidities

Authors: W Powderly

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O25

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
0232. HIV therapy in an ageing population — the challenge of polypharmacy

Authors: DJ Back

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O26

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
0233. Impact on life expectancy of late diagnosis and treatment of HIV-1 infected individuals: UK CHIC

Authors: MT May, M Gompels and CA Sabin

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O27

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
0234. Mitochondrial ageing and antiretroviral therapy exposure

Authors: BAI Payne, CA Hateley, DC Samuels, IJ Wilson, M Santibanez-Koref, DA Price and PF Chinnery

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O28

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
0311. Hepatitis C new drugs

Authors: H Wedemeyer

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O29

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
0312. Host genetics of HCV disease — IL28B

Authors: J Fellay

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O30

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
0313. Hepatitis C — feedback from the Consensus Conference on the Management of Acute Hepatitis C (AHC) in Paris, May 2010

Authors: M Vogel

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O31

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
0314. Efficacy and safety of peginterferon alfa-2a + RBV in cHCV/HIV- vs cHCV-infected patients: interim analysis of a multicenter German cohort

Authors: A Baumgarten, T Lutz, P Kreckel, E Wellmann, U Alshuth, S Mauss and J Rockstroh

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O32

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
0315. The pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers

Authors: J Ashby, LJ Garvey, OW Erlwein, H Lamba, R Weston, K Legg, MO McClure, L Dickinson, A D'Avolio, DJ Back and A Winston

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O33

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
How early to start: what do observational data suggest?

Authors: J Sterne

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O34

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
HIV/HAART and the brain — what's going on?

Authors: P Portegies

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O35

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
Adolescents with perinatally acquired HIV — coming your way

Authors: C Foster

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O36

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
Early mortality following ART initiation in HIV-infected adults and children in Uganda and Zimbabwe

Authors: AS Walker, P Mugyenyi, P Munderi, J Hakim, AA Kekitiinwa, E Katabira, CF Gilks, C Kityo, P Nahirya-Ntege, K Nathoo and D Gibb

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O37

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
Highlights of the 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, London, November 2010

Authors: M Schambelan

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O38

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
Fatal and non-fatal AIDS and non-AIDS events in HIV-1 infected patients with high CD4 counts

Authors: J Reekie, J Gatell, I Yust, E Bakowska, A Rachmanova, M Losso, M Krasnov, P Francioli, J Kowalska and A Mocroft

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O39

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
Cardiovascular risk assessment in persons with HIV in the developing world: comparing three risk equations in a cohort of HIV-infected Thais

Authors: N Edwards-Jackson, SJ Kerr, HV Tieu, J Ananworanich, SM Hammer, K Ruxrungtham, P Phanuphak and A Avihingsanon

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O40

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
What affects the bone in our HIV-positive patients?

Authors: CA Fux

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O41

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
Vitamin D and HIV: shine a light

Authors: J Currier

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O42

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study

Authors: JP Viard, JC Souberbielle, O Kirk, B Knysz, M Losso, J Gatell, C Pedersen, JR Bogner, A Mocroft and JD Lundgren

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O43

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART

Authors: S Rusconi, P Vitiello, F Adorni, E Colella, E Focà, AF Capetti, P Meraviglia, C Abeli, S Bonora, M D'Annunzio, A Di Biagio, A Di Pietro, L Butini, G Orofino, S Farina, G d'Ettorre…

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O44

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program

Authors: A Lazzarin, JG Sierra-Madero, M Battegay, G Mukwaya, R Burnside, D Chapman, J McCracken, S Portsmouth, S Valluri, H Valdez and J Heera

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O45

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
HIV entry blocked by maraviroc can cause an overestimation of viral load

Authors: RD Sloan, BD Kuhl, VG Kramer, DA Donahue, T Bar-Magen, R Tressler and MA Wainberg

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O46

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF
The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients

Authors: HJ Stellbrink, S Rugina, C Zagler, S Esser, A Castagna, B Gazzard, A Hill, Y van Delft and S Marks

Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O47

Content type: Oral presentation Published on: 8 November 2010
- View Full Text
- View PDF

Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection

Meeting abstracts

Journal of the International AIDS Society